Inhibikase Therapeutics Inc (IKT)

Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India

Mar 31, 2025

Mar 30, 2025

HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World

Mar 30, 2025

Mar 29, 2025

Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 29, 2025

Mar 27, 2025

Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz

Mar 27, 2025

Mar 27, 2025

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan

Mar 27, 2025

Mar 23, 2025

INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025

Mar 21, 2025

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 05, 2025

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research

Mar 05, 2025

Feb 25, 2025

After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury

Feb 25, 2025

Feb 24, 2025

Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria

Feb 24, 2025

Feb 24, 2025

Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire

Feb 24, 2025

Feb 24, 2025

Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com

Feb 24, 2025

Feb 24, 2025

Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks

Feb 24, 2025

Feb 24, 2025

Inhibikase enhances leadership with new appointments - Investing.com

Feb 24, 2025

Feb 24, 2025

Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World

Feb 24, 2025

Feb 18, 2025

Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks

Feb 18, 2025

Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan

Feb 18, 2025

Feb 17, 2025

What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World

Feb 17, 2025

Feb 15, 2025

HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN

Feb 15, 2025

Feb 15, 2025

Inhibikase Therapeutics (NYSE:IKT) Lowered to Neutral Rating by HC Wainwright - MarketBeat

Feb 15, 2025

Feb 15, 2025

Inhibikase Therapeutics (NYSE:IKT) Cut to Neutral at HC Wainwright - Defense World

Feb 15, 2025

Feb 12, 2025

HC Wainwright & Co. Downgrades Inhibikase Therapeutics (MUN:IQT0) - Nasdaq

Feb 12, 2025

Feb 12, 2025

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Feb 12, 2025

Feb 12, 2025

HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy -February 12, 2025 at 07:59 am EST - Marketscreener.com

Feb 12, 2025

Feb 01, 2025

Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 2.5%What's Next? - MarketBeat

Feb 01, 2025

Jan 31, 2025

Inhibikase Thera falls as risvodetinib development paused - The Pharma Letter

Jan 31, 2025

Jan 31, 2025

Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St

Jan 31, 2025

Jan 30, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 30, 2025

Jan 30, 2025

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - MSN

Jan 30, 2025

Jan 30, 2025

Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN

Jan 30, 2025

Jan 30, 2025

Stock market today: Aclarion -99.69%, CARGO Therapeutics -76.31% among biggest losers in early trading - Business Upturn

Jan 30, 2025

Jan 30, 2025

Inhibikase shelves Parkinson’s asset after Phase 2 flop - Endpoints News

Jan 30, 2025

Jan 28, 2025

Inhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% – Should You Sell? - Defense World

Jan 28, 2025

Jan 21, 2025

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing R - GuruFocus.com

Jan 21, 2025

Jan 21, 2025

Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock - Yahoo Finance

Jan 21, 2025

Jan 15, 2025

Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR

Jan 15, 2025

Jan 13, 2025

Top 5 Small-cap Pharma Stocks (Updated January 2025) - Investing News Network

Jan 13, 2025

Jan 07, 2025

Inhibikase Therapeutics Completes Amendment to Certificate of IncorporationAtlanta, Georgia – Inhibikase Therapeutics, Inc. (NYSE:IKT) recently announced the successful completion of a Special Meeting of Stockholders on January 3, 2025. During this m - Defense World

Jan 07, 2025

Jan 06, 2025

Inhibikase Therapeutics expands authorized shares - Investing.com India

Jan 06, 2025

Jan 06, 2025

Inhibikase Therapeutics expands authorized shares By Investing.com - Investing.com Australia

Jan 06, 2025

Dec 28, 2024

Contrasting CRISPR Therapeutics (NASDAQ:CRSP) & Inhibikase Therapeutics (NYSE:IKT) - Defense World

Dec 28, 2024

Dec 27, 2024

Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% HigherTime to Buy? - MarketBeat

Dec 27, 2024

Dec 27, 2024

Inhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher – Still a Buy? - Defense World

Dec 27, 2024

Dec 20, 2024

Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com

Dec 20, 2024

Dec 20, 2024

Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com

Dec 20, 2024

Dec 16, 2024

Inhibikase Therapeutics Hits 52-Week High, Surpassing Market Expectations with 198% Growth - mediahousepress

Dec 16, 2024

Dec 16, 2024

Inhibikase stock soars to 52-week high, hits $3.88 - Investing.com

Dec 16, 2024